AKT1 and ovarian carcinoma: Similar findings were reported by a study on ovarian cancer cell lines, in which mifepristone reduced gap closure [44], and this was linked to an inhibitory effect of mifepristone on the SDF-1/CXCR-4 axis with downstream suppression of the PI3K-Akt and MAPK signalling pathways.